Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma.
- DOI
- 10.1016/j.urolonc.2025.110989
- Published
- 2026-01-22
- Container
- Urol Oncol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.urolonc.2025.110989,
title = {Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma.},
author = {Tsimafeyeu I and Guliyev F and Ongarbayev B and Musaeva G and Abdrakhmanov R and Chubenko V and Baklanova O and Zukov R and Petkau V and Kaidarova D.},
year = {2026},
journal = {Urol Oncol},
doi = {10.1016/j.urolonc.2025.110989},
url = {https://doi.org/10.1016/j.urolonc.2025.110989}
}RIS
TY - JOUR TI - Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma. AU - Tsimafeyeu I AU - Guliyev F AU - Ongarbayev B AU - Musaeva G AU - Abdrakhmanov R AU - Chubenko V AU - Baklanova O AU - Zukov R AU - Petkau V AU - Kaidarova D. PY - 2026 JO - Urol Oncol DO - 10.1016/j.urolonc.2025.110989 UR - https://doi.org/10.1016/j.urolonc.2025.110989 ER -
APA
I, T., F, G., B, O., G, M., R, A., V, C., O, B., R, Z., V, P., & D., K. (2026). Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma.. Urol Oncol. https://doi.org/10.1016/j.urolonc.2025.110989
Source records
- europe-pmc · retrieved 2026-09-26T15:17:23.667Z